Matches in SemOpenAlex for { <https://semopenalex.org/work/W1777587551> ?p ?o ?g. }
- W1777587551 endingPage "69" @default.
- W1777587551 startingPage "61" @default.
- W1777587551 abstract "WHO has targeted that medicines to prevent recurrent cardiovascular disease be available in 80% of communities and used by 50% of eligible individuals by 2025. We have previously reported that use of these medicines is very low, but now aim to assess how such low use relates to their lack of availability or poor affordability.We analysed information about availability and costs of cardiovascular disease medicines (aspirin, β blockers, angiotensin-converting enzyme inhibitors, and statins) in pharmacies gathered from 596 communities in 18 countries participating in the Prospective Urban Rural Epidemiology (PURE) study. Medicines were considered available if present at the pharmacy when surveyed, and affordable if their combined cost was less than 20% of household capacity-to-pay. We compared results from high-income, upper middle-income, lower middle-income, and low-income countries. Data from India were presented separately given its large, generic pharmaceutical industry.Communities were recruited between Jan 1, 2003, and Dec 31, 2013. All four cardiovascular disease medicines were available in 61 (95%) of 64 urban and 27 (90%) of 30 rural communities in high-income countries, 53 (80%) of 66 urban and 43 (73%) of 59 rural communities in upper middle-income countries, 69 (62%) of 111 urban and 42 (37%) of 114 rural communities in lower middle-income countries, eight (25%) of 32 urban and one (3%) of 30 rural communities in low-income countries (excluding India), and 34 (89%) of 38 urban and 42 (81%) of 52 rural communities in India. The four cardiovascular disease medicines were potentially unaffordable for 0·14% of households in high-income countries (14 of 9934 households), 25% of upper middle-income countries (6299 of 24,776), 33% of lower middle-income countries (13,253 of 40,023), 60% of low-income countries (excluding India; 1976 of 3312), and 59% households in India (9939 of 16,874). In low-income and middle-income countries, patients with previous cardiovascular disease were less likely to use all four medicines if fewer than four were available (odds ratio [OR] 0·16, 95% CI 0·04-0·57). In communities in which all four medicines were available, patients were less likely to use medicines if the household potentially could not afford them (0·16, 0·04-0·55).Secondary prevention medicines are unavailable and unaffordable for a large proportion of communities and households in upper middle-income, lower middle-income, and low-income countries, which have very low use of these medicines. Improvements to the availability and affordability of key medicines is likely to enhance their use and help towards achieving WHO's targets of 50% use of key medicines by 2025.Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, AstraZeneca (Canada), Sanofi-Aventis (France and Canada), Boehringer Ingelheim (Germany and Canada), Servier, GlaxoSmithKline, Novartis, King Pharma, and national or local organisations in participating countries." @default.
- W1777587551 created "2016-06-24" @default.
- W1777587551 creator A5002295278 @default.
- W1777587551 creator A5003283304 @default.
- W1777587551 creator A5005449207 @default.
- W1777587551 creator A5005906845 @default.
- W1777587551 creator A5012111658 @default.
- W1777587551 creator A5013408607 @default.
- W1777587551 creator A5016340724 @default.
- W1777587551 creator A5017145273 @default.
- W1777587551 creator A5018011410 @default.
- W1777587551 creator A5018419311 @default.
- W1777587551 creator A5022813675 @default.
- W1777587551 creator A5023361030 @default.
- W1777587551 creator A5026568725 @default.
- W1777587551 creator A5027320968 @default.
- W1777587551 creator A5039145780 @default.
- W1777587551 creator A5043108140 @default.
- W1777587551 creator A5043684388 @default.
- W1777587551 creator A5045264049 @default.
- W1777587551 creator A5050936489 @default.
- W1777587551 creator A5054103199 @default.
- W1777587551 creator A5055200248 @default.
- W1777587551 creator A5058694063 @default.
- W1777587551 creator A5061519671 @default.
- W1777587551 creator A5065568572 @default.
- W1777587551 creator A5069728608 @default.
- W1777587551 creator A5077219405 @default.
- W1777587551 creator A5077740991 @default.
- W1777587551 creator A5080920662 @default.
- W1777587551 creator A5081312292 @default.
- W1777587551 creator A5083663995 @default.
- W1777587551 creator A5086287744 @default.
- W1777587551 creator A5087440857 @default.
- W1777587551 date "2016-01-01" @default.
- W1777587551 modified "2023-09-29" @default.
- W1777587551 title "Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data" @default.
- W1777587551 cites W2040900080 @default.
- W1777587551 cites W2045541573 @default.
- W1777587551 cites W2058939989 @default.
- W1777587551 cites W2086015900 @default.
- W1777587551 cites W2098194481 @default.
- W1777587551 cites W2109317822 @default.
- W1777587551 cites W2122047846 @default.
- W1777587551 cites W2125849337 @default.
- W1777587551 cites W2129051534 @default.
- W1777587551 cites W2132816662 @default.
- W1777587551 cites W2135383573 @default.
- W1777587551 cites W2136786020 @default.
- W1777587551 cites W2144663588 @default.
- W1777587551 cites W2151739272 @default.
- W1777587551 cites W2155468870 @default.
- W1777587551 cites W2156260018 @default.
- W1777587551 cites W2161339587 @default.
- W1777587551 doi "https://doi.org/10.1016/s0140-6736(15)00469-9" @default.
- W1777587551 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26498706" @default.
- W1777587551 hasPublicationYear "2016" @default.
- W1777587551 type Work @default.
- W1777587551 sameAs 1777587551 @default.
- W1777587551 citedByCount "255" @default.
- W1777587551 countsByYear W17775875512015 @default.
- W1777587551 countsByYear W17775875512016 @default.
- W1777587551 countsByYear W17775875512017 @default.
- W1777587551 countsByYear W17775875512018 @default.
- W1777587551 countsByYear W17775875512019 @default.
- W1777587551 countsByYear W17775875512020 @default.
- W1777587551 countsByYear W17775875512021 @default.
- W1777587551 countsByYear W17775875512022 @default.
- W1777587551 countsByYear W17775875512023 @default.
- W1777587551 crossrefType "journal-article" @default.
- W1777587551 hasAuthorship W1777587551A5002295278 @default.
- W1777587551 hasAuthorship W1777587551A5003283304 @default.
- W1777587551 hasAuthorship W1777587551A5005449207 @default.
- W1777587551 hasAuthorship W1777587551A5005906845 @default.
- W1777587551 hasAuthorship W1777587551A5012111658 @default.
- W1777587551 hasAuthorship W1777587551A5013408607 @default.
- W1777587551 hasAuthorship W1777587551A5016340724 @default.
- W1777587551 hasAuthorship W1777587551A5017145273 @default.
- W1777587551 hasAuthorship W1777587551A5018011410 @default.
- W1777587551 hasAuthorship W1777587551A5018419311 @default.
- W1777587551 hasAuthorship W1777587551A5022813675 @default.
- W1777587551 hasAuthorship W1777587551A5023361030 @default.
- W1777587551 hasAuthorship W1777587551A5026568725 @default.
- W1777587551 hasAuthorship W1777587551A5027320968 @default.
- W1777587551 hasAuthorship W1777587551A5039145780 @default.
- W1777587551 hasAuthorship W1777587551A5043108140 @default.
- W1777587551 hasAuthorship W1777587551A5043684388 @default.
- W1777587551 hasAuthorship W1777587551A5045264049 @default.
- W1777587551 hasAuthorship W1777587551A5050936489 @default.
- W1777587551 hasAuthorship W1777587551A5054103199 @default.
- W1777587551 hasAuthorship W1777587551A5055200248 @default.
- W1777587551 hasAuthorship W1777587551A5058694063 @default.
- W1777587551 hasAuthorship W1777587551A5061519671 @default.
- W1777587551 hasAuthorship W1777587551A5065568572 @default.
- W1777587551 hasAuthorship W1777587551A5069728608 @default.
- W1777587551 hasAuthorship W1777587551A5077219405 @default.
- W1777587551 hasAuthorship W1777587551A5077740991 @default.
- W1777587551 hasAuthorship W1777587551A5080920662 @default.